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sequence typeBackground/Purpose: The aim of this study was to investigate clinical presentation, serotype
distribution and genetic correlation of group B streptococcus (GBS) diseases. Since serotype VI
prevalence far exceeded that reported in prior studies, genetic relationship of isolates was
further analyzed.
Methods: GBS isolates obtaining from patients with invasive diseases and pregnant women
with colonization between June 2007 and December 2010 were analyzed. All isolates were
tested for serotypes by multiplex PCR assay and pulsed-field gel electrophoresis (PFGE). Sero-
type VI isolates were further analyzed by multilocus sequence typing (MLST).
Results: A total of 134 GBS isolates were recovered from blood of 126 patients with invasive
disease (94.0%) and anogenital swabs of 8 pregnant women (6.0%). Most common serotype
was Ib (21.6%), followed by V (20.1%), VI (18.7%), III (15.7%), II (11.9 %), Ia (11.2%), and IX
(0.7%). Serotype VI was also the leading type in infants with early onset disease (EOD; 3/8,
37.5%) and colonizing pregnant women (3/8, 37.5%). PFGE distinguished 33 pulsotypes, reflect-
ing genetic diversity among GBS isolates. Among 25 serotype VI isolates tested, 14 were ST-1,
seven were ST-679, three were ST-678, one was ST-681, and distributed into four PFGE pulso-
types. ST-678, ST-679, and ST-681 were novel sequence types; ST-678 and ST-679 are single-
locus variants of ST-1 that belongs to clonal complex (CC) 1.
Conclusion: CC1 dissemination of serotype VI GBS thus emerges as an important invasive path-
ogen in infants and nonpregnant adults in central Taiwan. Serotype prevalence of GBS must be
continuously monitored geographically to guide prevention strategy of GBS vaccines.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Group B Streptococcus (GBS), also known as Streptococcus
agalactiae, is a major cause of invasive infection in neo-
nates, pregnant women, and nonpregnant adults older than
65 years or those immunocompromised by underlying
medical conditions.1e3 GBS, an encapsulated gram-positive
bacterium, colonizes human gastrointestinal, and genital
tracts. Neonates acquire colonization and infection with
GBS vertically, either in utero by the ascending route or at
delivery. Since initiation of maternal intrapartum chemo-
prophylaxis (IAP) in 1996 in the United States, the incidence
of early-onset disease (EOD) has declined by 65% compared
with the preprevention era baseline rate in 1993.4 Howev-
er, maternal IAP does not reduce the incidence of late-
onset disease (LOD).1,4 In addition to neonates, the
growing prevalence of invasive GBS disease in nonpregnant
adults has been reported, with common clinical syndromes
of bacteremia without focus, skin and/or soft-tissue
infection, and pneumonia.1e3 Most (88.0%) adult GBS
cases had underlying conditions, diabetes the most com-
mon (41.0e44.4%).1,2 Vaccinating pregnant women with
glycoconjugate vaccine could potentially prevent invasive
GBS diseases of newborns.5,6
By structure of surface capsular polysaccharide (CPS),
isolates were serotyped as Ia, Ib, IIeVIII, and provisional
IX.7 Serotypes Ia, Ib, II, III, and V accounted for 96% of
neonatal cases1,8 and 88e93% of adult cases,1e3 targets of
protective immunity, and candidates of GBS vaccines. By
contrast to these, serotype VI has been rarely cited in
Europe and America: 1% in infants younger than 90 days8
and 0.1% in nonpregnant adults,2 yet predominant in
Japan among GBS strains isolated from pregnant women
with colonization (5.6e24.7%)9e11 and neonates with EOD(8.5%).12 In Taiwan, the past 20 years have seen serotype VI
reported sporadically: 2.6% in patients with invasive dis-
ease during 1994e2004,13 and 4% between 2001 and 2004.14
Still, prevalence rose to 10.5% in nonpregnant patients
between 2006 and 200815 and 12% in cases of invasive dis-
ease from 1998 to 2009.16 To understand the epidemiology
of GBS diseases in central Taiwan, we collected GBS isolates
from invasive disease patients or pregnant women with
colonization, analyzing serotype distribution and genetic
correlation by pulse-field gel electrophoresis (PFGE). Since
serotype VI prevalence far exceeded that reported in prior
studies, genetic relationship of isolates was further
analyzed by multilocus sequence typing (MLST).Methods
GBS isolates
From June 2007 to December 2010, GBS isolates obtaining
from blood of patients with invasive diseases along with
anogenital swabs of colonizing pregnant women at China
Medical University Hospital (CMUH) in central Taiwan, were
analyzed. One isolate per patient was included, GBS strains
grouped by clinical outcome and anatomical isolation sites:
invasive strains from blood (nZ 126) and colonizing strains
from anogenital specimens (n Z 8). Case details were
gleaned from medical records. Primary bacteremia was
defined as the presence of viable bacteria in blood without
an obvious site of active infection. GBS disease in infants
was categorized as early onset disease (EOD; from birth to 6
day old), and late onset disease (LOD; aged 7e89 days).
This project was approved by the Institutional Review
Board of our hospital (DMR100-IRB-237-1).
904 H.-C. Lin et al.Identification and serotyping
Isolates cultured onto 5% sheep blood plate for 24 hours
at 37C in 5% CO2 atmosphere were identified according
to colony morphology, b-hemolysis, Gram staining, and
Lancefield grouping with type B antisera. Serotyping was
performed via multiplex PCR assay previously described by
Imperi et al.17
Antimicrobial susceptibility testing
Isolates were rated for susceptibility to penicillin, clinda-
mycin, and erythromycin, as per Clinical and Laboratory
Standards Institute guidelines by microdilution MIC
method.18 The double-disk diffusion test was applied to
uncover inducible clindamycin resistance.
Pulsed-field gel electrophoresis
Genomic DNA of all isolates was prepared and subsequently
digested by restriction endonuclease SmaI (New England
BioLabs, Beverly, MA, USA) as previously described,19 with
modification. After digestion, PFGE was performed on the
CHEF-DR III System (Bio-Rad Laboratories, Hercules, CA,
USA), with these parameters: switch time of 1e5 seconds
for 8 hours, 3.5e45 seconds for 12 hours; 6 V/cm; 14C;
120 angle. PFGE patterns were then examined with Bio-
numerics software (Applied Maths, Kortrijik, Belgium) and a
dendrogram was generated using the unweighted pair groupTable 1 Serotype distribution of group B streptococcus disease i
clinical manifestations, and resistance of erythromycin and clind
Clinical manifestation
or site
Total
(n Z 134) Ia
(n Z 15)
Ib
(n Z 29)
II
(n
Isolates
Colonizing isolates 8 (6.0) 0 (0.0) 1 (3.5) 0
Invasive isolates 126 (94.0) 15 (100.0) 28 (96.6) 16
Invasive isolates
according to age
Infant 17 (13.5) 3 (20.0) 1 (3.6) 0
EODa 8 2 1 0
LODb 9 1 0 0
Adolescent 1 (0.8) 0 (0.0) 1 (3.6) 0
Non-pregnant adults 108 (85.7) 12 (80.0) 26 (92.9) 16
Primary bacteremia 8 0 0 1
Sepsis 73 8 20 12
Sepsis & cellulitis 24 4 6 3
Sepsis & septic
arthritis/osteomyelitis
3 0 0 0
Death in invasive isolates 12 (9.5) 0 (0.0) 2 (7.1) 2
Isolates not susceptible to
Erythromycin 59 (44.0) 3 (20.0) 26 (89.7) 1
Clindamycin 55 (41.0) 2 (13.3) 25 (86.2) 0
Data were presented as n (%).
a EOD, early-onset disease.
b LOD, late-onset disease.
c p-value from Chi-square test or Fisher’s exact test.method with arithmetic mean (UPGMA) algorithm. The Dice
similarity coefficient was employed, with optimization po-
sition tolerance settings of 1.0% and 1.5%, respectively.
Isolates with similarities of 80% clustered as highly
genetically related and grouped as one pulsotype (PT).
Multilocus sequence typing
MLST evaluated 25 serotype VI isolates, sequencing seven
housekeeping genes, as originally described,20 sequence
type (ST) determined via Streptococcus agalactiae MLST
database (http://pubmlst.org/sagalactiae). Sequence
types not previously described were submitted and
assigned at the S. agalactiae MLST database.
Statistical analysis
Data were analyzed using SAS version 9.3 (SAS Institute,
Cary, NC). Trend over time was analyzed using logistic
regression analysis. Chi-square test or Fisher’s exact test
were used for the comparison of proportions; 2-tailed
p < .05 was considered to be statistically significant.
Results
A total of 134 GBS isolates were recovered from the blood
of 126 (94.0%) patients with invasive disease and anogenital
swabs of eight pregnant women (6%; Table 1). Among
invasive cases, infants had higher prevalence of serotype IIIn children, pregnant women and non-pregnant adults, by age,
amycin, 2007e2010
Isolate type p-valuec
Z 16)
III
(n Z 21)
V
(n Z 27)
VI
(n Z 25)
IX
(n Z 1)
0.608
(0.0) 2 (9.5) 2 (7.4) 3 (12.0) 0 (0.0)
(100.0) 19 (90.5) 25 (92.6) 22 (88.0) 1 (100.0)
0.001
(0.0) 9 (47.4) 1 (4.0) 3 (13.6) 0 (0.0)
2 0 3 0
7 1 0 0
(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
(100.0) 10 (52.6) 24 (96.0) 19 (86.4) 1 (100.0)
2 3 1 1
5 16 12 0
3 3 5 0
0 2 1 0
(12.5) 0 (0.0) 4 (16.0) 4 (18.2) 0 (0.0) 0.265
(6.3) 11 (52.4) 12 (44.4) 6 (24.0) 0 (0.0) <.001
(0.0) 10 (47.6) 12 (44.4) 6 (24.0) 0 (0.0) <.001
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of serotypes Ib, II, V, and VI. Among patients with invasive
diseases, the overall mortality was 9.5 % (12/126), and
mortality did not differ with regard to serotypes
(pZ 0.265). Clinical presentations of 17 infants emerged as
8 EOD and 9 LOD. One adolescent with acute lymphocytic
leukemia had sepsis. Of 108 nonpregnant adults (57% fe-
male), the most common manifestation was sepsis (nZ 73,
68%), followed by sepsis with cellulitis (n Z 24, 22%), pri-
mary bacteremia (n Z 8, 7%), and sepsis with arthritis/
osteomyelitis (n Z 3, 3%).
Overall, types Ib (n Z 29, 21.6%) and V (n Z 27, 19.1%)
were predominant, followed by VI (n Z 25, 18.7%), III
(nZ 21, 15.7%), II (nZ 16, 11.9%), Ia (nZ 15, 11.2%), and
IX (n Z 1, 0.7%) (Table 1). Type III was most common in
infants and type VI (37.5%) in infants with EOD. Of 108
nonpregnant adults, Type Ib (24.1%) was the most frequent
and Type VI (17.5%) was third. Type VI (37.5%) was also the
most common in colonizing isolates. Every isolate proved
susceptible to penicillin; still, 44% (59/134) and 41% (55/
134) of strains were resistant to erythromycin and clin-
damycin, respectively. Inducible clindamycin resistance
was not detected in these strains. Serotype Ib showed
highest resistance to erythromycin (86%) (p < .001) and
clindamycin (90%) (p < .001). (Table 1) Among 25 serotype
VI isolates, resistance rates to erythromycin and clinda-
mycin both tallied 24% (Tables 1 and 2). The proportion
of invasive serotype VI increased from 12.5% in 2007 to
15.9% (unpublished data, CMUH) in 2012, but the
increasing trend was not statistically significant (P for
trend Z 0.9236).
Isolates were assessed with PFGE, 33 pulsotypes
distinguished by Dendrogram (Fig. 1). We defined a major
pulsotype as comprising at least five strains: i.e., six major
PFGE pulsotypes (3, 4, 18, 25, 26, 27) containing 96 (72%)
of 134 isolates (Table 3, Fig. 1), with pulsotype 27 (25%,
34/134) the most common. Serotypes Ib and V were the
most homogenous; Ia, II, III, and VI were heterogenous,
each contained two or three pulsotypes (Table 3). Pulso-
types 3, 4, and 25 contained solely isolates of serotypes Ia,
III, and VI, respectively. Pulsotypes 18, 26, and 27 showed
more diversity: each comprised two or three serotypes
(Table 3).
Table 2 depicts clinical data of 25 patients infected or
colonized with serotype VI isolates, distributed into four
pulsotypes. Pulsotype 26 was the most common, accounting
for 64% (n Z 16) of 25 isolates; six (24%) pulsotype 25, two
(8%) pulsotype 28, and one (4%) pulsotype 29. The 25
serotype VI isolates studied by MLST contained four
sequence types, including ST-1 (n Z 14), and three novel
STs, ST-678 (allelic profile 1,37,2,1,1,2,2) (n Z 3), ST-679
(allelic profile 1,9,2,1,1,2,2) (n Z 7), and ST-681 (allelic
profile 35,2,2,1,1,2,2) (n Z 1). ST-678, ST-679, and ST-681
had never been defined before this study. All but one
serotype VI isolate (Patient 12, ST-681) displayed ST-1 or
single-locus variant (SLV) of it (ST-678 and ST-679),
belonging to clonal complex (CC) 1. Isolates from three
neonates with EOD and three pregnant women with colo-
nization were ST-1 (n Z 4) or ST-679 (n Z 2). Four
nonpregnant adults with sepsis and underlying conditions
died. No correlation surfaced between pulsotypes, STs, and
isolation dates.Discussion
In this study, serotype VI was predominant in EOD infants
(3/8, 37.5%) and colonized pregnant women (3/8, 37.5%),
ranking third (17.5%) among nonpregnant adults with inva-
sive infection. Overall, 25 isolates (18.7%) belonged to
serotype VI in 134 GBS isolates; 96% of them ST-1, ST-678, or
ST-679 (the latter 2 SLVs of ST-1), based on MLST analysis
and belonging to clonal complex (CC) 1, divided into four
pulsotypes. Previous studies disclosed 9.4%213 to 12%16
prevalence of serotype VI in southern and northern
Taiwan. Therefore, prevalence of 18.7% in this study points
to cloncal dissemination of serotype VI GBS, CC1as an
important pathogen in central Taiwan.
Earlier (1994e2004) study in southern Taiwan identified
only 2.6% invasive isolates as serotype VI.13 A 1998e2009
study in northern Taiwan disclosed its emergence in
nonpregnant adults with invasive GBS disease, 12% preva-
lence.16 In addition, 10.5% of GBS isolates from nonpreg-
nant patients were serotype VI in southern Taiwan
(2006e2008).15 A recent study in southern Taiwan
(2008e2010) unveiled 9.4% isolates obtaining from hospi-
talized non-pregnant adults as serotype VI.21 Based on up-
ward trends of serotype VI GBS in Taiwan,13,15,16,21
Japan,10,11,22 Malaysia,23 ThaieMyanmar border,24 and our
current study (18.7%), it is possible that type VI has
emerged as a prominent pathogen in Taiwan since the late
1990s and in Asia since the mid 1980s.
Invasive GBS serotypes vary among geographic regions
and age groups.2,8 Globally, in infants younger than 90
days, the main serotypes were III (49%) and Ia (23%).8 This
study showed similar results, but type Ib (21.6%) was most
common in nonpregnant adults, sharply differing from
Skoff et al2 where serotypes V (29.2%), Ia (24.3%), II
(13.5%), and III (11.4%) were predominant. In our study,
17.5% of invasive and 37.5% of colonizing strains were
serotype VI, far higher than previous studies: 1% in infants
<90 days old8 and 0.1% in nonpregnant adults.2 In addition,
our study showed that serotype VI strains obtained from
term infants with EOD and colonized pregnant women tal-
lied 37.5%. Further evidence arose from our 2011e2012
surveillance: 14% (19/136) invasive and 13.6% (9/66) colo-
nizing isolates from pregnant women were serotype VI
(unpublished CMUH data). Serotype VI was first detected in
1977 at the Centers for Disease Control, Atlanta.25 A ma-
jority of serotype VI distributed in Japan since the mid
1980s accounted for 5.6e26.6% in pregnant women with
colonization10,11,22 and EOD (8.5%).12 Pregnant women
colonized with it were also common in Malaysia (17%),23
ThaieMyanmar border (16.7%),24 and Iran (12.5%).26
Nonetheless, serotype VI has been reported sporadically
in America,27 Korea,28 Greece,29 The Netherlands,30
Kuwait,31 and Australia.32
Besides ST1, novel sequence types 678 and 679, SLV of
ST1 never reported, belonging to CC1, were exhibited by
serotype VI in this study. In addition, an earlier study
(2001e2004) revealed two strains of serotype VI GBS with
CC1 (ST1).14 Noninvasive serotype VI GBS strains with
reduced penicillin susceptibility belonging to ST1 and ST-
458 (a SLV of ST-1) were reported in Japan.33,34 Wong
et al16 noted emergence of serotype VI GBS as an invasive
Table 2 Clinical data and general characteristics of 25 serotype VI GBS isolates from patients with invasive GBS disease or colonization during 2007e2010
Patient Specimen
ID
Date
(mo/yr)
Age
(yr)/Sex
Clinical syndrome Underlying
Diseasesb
Outcome Pulsotypes MLSTc Clindamycin
susceptibilitya
Erythromycin
susceptibilitya
1 012 11/2007 31/F Colonization Survived 25 ST-1 R R
2 034 11/2007 67/F Sepsis L Survived 25 ST-1 R R
3 067 05/2009 54/F Sepsis & cellulitis DM, M Survived 25 ST-679 S S
4 096 10/2009 57/M Sepsis & osteomyelitis DM, L Survived 25 ST-1 S S
5 135 07/2010 35/F Sepsis & cellulitis M Survived 25 ST-679 S S
6 137 07/2010 60/M sepsis M, L Survived 25 ST-1 S S
7 002 06/2007 71/M Sepsis & cellulitis DM, M, L Survived 26 ST-678 S S
8 014 11/2007 33/F Colonization Survived 26 ST-1 S S
9 020 11/2007 26/F Colonization Survived 26 ST-679 S S
10 040 04/2008 1d/F EOD & sepsis Survived 26 ST-679 S S
11 060 03/2009 77/F Sepsis DM, M Survived 26 ST-1 S S
12 065 04/2009 69/F Sepsis DM Survived 26 ST-1 S S
13 079 07/2009 59/F Sepsis Survived 26 ST-681 S S
14 089 09/2009 1d/M EOD & sepsis Survived 26 ST-1 S S
15 102 12/2009 62/M Sepsis r Survived 26 ST-1 S S
16 107 01/2010 83/M Sepsis DM, L Died 26 ST-679 R R
17 112 03/2010 63/M Sepsis L, r Died 26 ST-1 S S
18 117 03/2010 54/M Sepsis M, L Died 26 ST-1 R R
19 119 03/2010 1d/M EOD & sepsis Survived 26 ST-1 R R
20 124 04/2010 84/M Primary bacteremia DM Survived 26 ST-679 S S
21 134 07/2010 83/M Sepsis L Survived 26 ST-678 S S
22 136 07/2010 86/M Sepsis M Survived 26 ST-679 S S
23 055 12/2008 41/M Sepsis DM, L Survived 28 ST-1 S S
24 083 07/2009 59/M Sepsis & cellulitis M Survived 28 ST-678 S S
25 024 09/2007 54/M Sepsis M Died 29 ST-1 R R
a S, susceptible, MIC <0.25 mg/mL; R, resistant, MIC 1mg/mL.
b DM, diabetes mellitus; L, liver diseases; M, malignancy; r: renal diseases.
c Multilocus sequence type of 7 housekeeping genes (adhP, pheS, atr, glnA, sdhA, glcK, tkt). Allelic profiles of ST-1 (1, 1, 2, 1, 1, 2, 2);
ST-678 (1, 37, 2, 1, 1, 2, 2); ST-679 (1, 9, 2, 1, 1, 2, 2); ST-681 (35, 2, 2, 1, 1, 2, 2).
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Figure 1. Phylogenitic analysis of the pulsed field gel elec-
trophoresis (PFGE) profiles of 134 GBS strains obtained during
2007e2010. The dendrogram was concocted by the unweighted
pair group method with arithmetic mean (UPGMA) algorithm.
Pulsotypes, shown to the right of the dendrogram with PFGE-
80, were termed as strains clustering on the dentrogram at
an 80% similarity cutoff point. Additionally denoted are isolates
designation and serotype by multiplex-PCR identified in each
isolate.
Table 3 Major pulsotypescorrelating with serotype among
96 of 134 GBS isolates during 2007-2010
PFGE
Pulsotypes
No. of isolates in each serotype
Total Ia Ib II III V VI
3 5 5
4 7 7
18 25 24 1
25 6 6
26 19 2 1 16
27 34 1 12 21
Total 96 8 24 13 8 21 22
Clonal dissemination of serotype VI GBS in Taiwan 907pathogen since 2006 in northern Taiwan, later in southern
Taiwan by Wang et al. after 2008.21 Specific clone CC1
serotype VI might play a role in vertical transmission in
cases with EOD from colonized pregnant women and inva-
sive disease in immunocompromised nonpregnant adults in
central Taiwan. Serotype VI should be considered for
developing glycoconjugated GBS vaccine in Asia.
Our research found pulsotypes 3, 4, and 25 shared by
isolates with specific serotypes, whereas pulsotypes 18,
21, 26, and 27 consisted of isolates belonging to two or
three serotypes (Table 3, Fig. 1). Serotypes Ib and V were
most homogenous, with unique pulsotypes; Ia, II, III, and VI
heterogenous, including two or three pulsotypes and
indicating greater genetic diversity. Similar heterogeneity
between serotypes and PFGE pulsotypes has been reported
in southern Brazil,35 Italy,36 and America.37 Cieslewicz
et al38 viewed GBS capsular polysaccharide structural di-
versity as driven by horizontal gene transfer, through the
introduction of novel DNA sequence and genetic recom-
bination. Martins et al37 later unearthed clear evidence for
in vivo capsular switching in Streptococcus agalactiae.
Classical and convenient typing by bacteria capsular
polysaccharide composition fails to mirror genetic di-
versity of species.39
The main limitation of this study is the small sample
size, especially in infants and colonized pregnant women.
Still, to our knowledge, this is the largest case series of
invasive serotype VI GBS infection by strains belonging to
genetic lineage CC1, regarding detailed clinical manifes-
tations, PFGE, and MLST studies, particularly in infants,
pregnant women, and nonpregnant adults. Immunizing
pregnant women with capsular (CPS)-based conjugate
vaccines (Ia, Ib, II, III, V), prevalent serotypes found in
North America and Europe, could potentially prevent
invasive GBS disease of newborns.37 These provide no
essential protection for individuals in areas where pre-
dominant capsular types such as serotype VI have arisen.
The resistance to clindamycin and erythromycin in serotype
VI GBS isolates from pregnant cases with colonization and
newborns with EOD is also alarming. Neonatal GBS infection
was still a common threat in Taiwan, with incidence of 1
per 1000 live births of infants during 2001e2005.40 Consid-
ering geographical location, the emergence of type VI, CC1
GBS strains in central Taiwan mandates inclusion in the GBS
vaccine in Asia for pregnant women. GBS serotype distri-
bution should be continuously monitored to guide preven-
tion strategies, such as effective vaccines.
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